{
    "organizations": [],
    "uuid": "02867f7c7a5bfd2366135fd3f8cfab3f31149ac4",
    "author": "",
    "url": "https://www.reuters.com/article/brief-intellipharmaceutics-meets-with-fd/brief-intellipharmaceutics-meets-with-fda-regarding-oxycodone-er-nda-development-program-idUSFWN1PZ197",
    "ord_in_thread": 0,
    "title": "BRIEF-Intellipharmaceutics Meets With FDA Regarding Oxycodone Er NDA Development Program",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 32 PM / Updated 14 minutes ago BRIEF-Intellipharmaceutics Meets With FDA Regarding Oxycodone Er NDA Development Program   Intellipharmaceutics International Inc : \n* INTELLIPHARMACEUTICS MEETS WITH FDA REGARDING OXYCODONE ER NDA DEVELOPMENT PROGRAM \n* INTELLIPHARMACEUTICS INTERNATIONAL - BASED ON MEETING WITH FDA, OXYCODONE ER WILL NO LONGER INCLUDE THE BLUE DYE IN IT \n* INTELLIPHARMACEUTICS INTERNATIONAL- FDA CONFIRMED REMOVAL OF BLUE DYE IN OXYCODONE ER UNLIKELY TO HAVE IMPACT ON ITS FORMULATION QUALITY, PERFORMANCE \n* INTELLIPHARMACEUTICS INTERNATIONAL - WILL NOT BE REQUIRED TO REPEAT IN VIVO BIOEQUIVALENCE STUDIES & PHARMACOKINETIC STUDIES SUBMITTED IN OXYCODONE ER NDA \n* INTELLIPHARMACEUTICS - FDA SAID, FROM ABUSE LIABILITY PERSPECTIVE,CATEGORY 1 STUDIES WILL NOT HAVE TO BE REPEATED ON OXYCODONE ER WITHOUT BLUE DYE Source text: ( bit.ly/2EwSmcQ )  ",
    "published": "2018-02-09T15:32:00.000+02:00",
    "crawled": "2018-02-09T15:49:54.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "meet",
        "fda",
        "regarding",
        "oxycodone",
        "er",
        "nda",
        "development",
        "program",
        "intellipharmaceutics",
        "international",
        "inc",
        "intellipharmaceutics",
        "meet",
        "fda",
        "regarding",
        "oxycodone",
        "er",
        "nda",
        "development",
        "program",
        "intellipharmaceutics",
        "international",
        "based",
        "meeting",
        "fda",
        "oxycodone",
        "er",
        "longer",
        "include",
        "blue",
        "dye",
        "intellipharmaceutics",
        "fda",
        "confirmed",
        "removal",
        "blue",
        "dye",
        "oxycodone",
        "er",
        "unlikely",
        "impact",
        "formulation",
        "quality",
        "performance",
        "intellipharmaceutics",
        "international",
        "required",
        "repeat",
        "vivo",
        "bioequivalence",
        "study",
        "pharmacokinetic",
        "study",
        "submitted",
        "oxycodone",
        "er",
        "nda",
        "intellipharmaceutics",
        "fda",
        "said",
        "abuse",
        "liability",
        "perspective",
        "category",
        "study",
        "repeated",
        "oxycodone",
        "er",
        "without",
        "blue",
        "dye",
        "source",
        "text"
    ]
}